 "Alembic Pharma's Q1 net up by 45% at Rs 102 cr")
The company's net sales rose by 25 per cent to Rs 735.78 crore in the Q1 in current financial year as against Rs 589.53 crore. It has registered 72 per cent growth in its international formulation business to stand at Rs 308 crore in the quarter.
"We continue to invest on research and development for further growth. Alembic USA was successfully established and has launched 23 products in the market," said Pranav Amin, managing director of Alembic Pharmaceutical Ltd.
Profit before tax (PBT) of the company gained 51 per cent to Rs 136.90 crore at the end of Q1 of FY'17 as against Rs 90.84 crore in the corresponding period of previous year.
Alembic's India branded formulation has increased 6 per cent to Rs 277.74 crore in Q1 of FY '17 as against Rs 262.75 crore for the said period last year. On the other hand, India generic formulation business of Alembic has declined by 23 per cent to Rs 21.32 crore from Rs 27.80 crore, the company stated.